CA-074: Selective Cathepsin B Inhibitor for Cancer and Neurotoxicity Research

Executive Summary: CA-074 is a small molecule inhibitor with high selectivity for cathepsin B (Ki = 2–5 nM), with negligible affinity for cathepsin H and L (Ki = 40–200 µM) [APExBIO]. Cathepsin B is a lysosomal cysteine protease essential in proteolytic pathways underlying tumor metastasis, regulated cell death, and immune modulation [Liu et al., 2023]. CA-074 has demonstrated efficacy in suppressing bone metastasis in breast cancer mouse models and reducing neurotoxicity induced by Abeta42-activated microglia. The compound is characterized by high solubility and low cytotoxicity, making it indispensable for translational research. Mechanistic studies show that inhibition of cathepsin B can protect cells from necroptosis and modulate Th-2/Th-1 immune responses.

Biological Rationale

Cathepsin B is a lysosomal cysteine protease involved in protein degradation, cell death, and immune regulation [Liu et al., 2023]. Dysregulated cathepsin B activity contributes to pathological conditions, including cancer invasion, metastasis, and neurodegeneration. Lysosomal membrane permeabilization (LMP) results in the cytosolic release of cathepsin B, triggering downstream proteolytic cascades that can lead to necroptosis or apoptotic cell death. In cancer, cathepsin B facilitates extracellular matrix degradation, promoting tumor cell invasion and metastatic spread. In neurodegeneration, excessive cathepsin B activity mediates neuronal cell death and inflammation. Thus, selective inhibition of cathepsin B is a validated strategy to interrogate these pathways.

Mechanism of Action of CA-074, Cathepsin B inhibitor

CA-074 ((2S)-1-[(2S,3S)-3-methyl-2-[[(3S)-3-(propylcarbamoyl)oxirane-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carboxylic acid, MW 383.44 g/mol) is an irreversible inhibitor targeting the active site of cathepsin B. Its nanomolar Ki (2–5 nM) for cathepsin B reflects strong and specific binding, with over 1,000-fold selectivity compared to cathepsin H and L (Ki = 40–200 µM) [APExBIO]. CA-074 covalently modifies the catalytic cysteine residue, disabling proteolytic activity. In cellular contexts, this blocks the cleavage of extracellular matrix proteins and the activation of downstream substrates involved in metastasis, inflammation, and cell death. In the context of necroptosis, MLKL polymerization triggers LMP, releasing cathepsin B into the cytosol; CA-074 prevents subsequent cell death by inhibiting cathepsin B’s proteolytic function [Liu et al., 2023].

Evidence & Benchmarks

• CA-074 inhibits cathepsin B with a Ki of 2–5 nM, providing >1,000-fold selectivity over cathepsin H and L (Ki 40–200 µM) (APExBIO).
• Chemical inhibition of cathepsin B by CA-074 protects against MLKL polymerization-induced necroptosis in human and mouse cell models (Liu et al. 2023).
• In vivo, CA-074 (50 mg/kg, i.p.) reduces bone metastasis in a 4T1.2 breast cancer mouse model without affecting primary tumor growth (APExBIO).
• In vitro, CA-074 shows negligible cytotoxicity at concentrations up to 10 mM in cell culture (APExBIO).
• CA-074 suppresses neurotoxic effects mediated by Abeta42-activated microglial cells (APExBIO).
• In immune studies, CA-074 shifts helper T cell activity from Th-2 to Th-1, reducing IgE and IgG1 antibody production (APExBIO).
• CA-074 is highly soluble in DMSO (>19.17 mg/mL), ethanol (>31.3 mg/mL), and water (>5.91 mg/mL with ultrasonic assistance) (APExBIO).
• Findings on necroptosis and cathepsin B's lethal protease activity are summarized in Liu et al., 2023 (DOI).

This article extends prior coverage, such as CA-074: Selective Cathepsin B Inhibitor for Cancer Metast..., by integrating the latest evidence on necroptosis and immune modulation, and offering updated practical parameters for laboratory use.

Applications, Limits & Misconceptions

Primary Applications

• Dissection of cathepsin B-dependent proteolytic pathways in cancer metastasis.
• Investigation of lysosome-mediated cell death (necroptosis) in oncology and immunology.
• Reduction of neurotoxicity in neurodegenerative models via microglial cathepsin B inhibition.
• Modulation of immune response, particularly Th-2 to Th-1 helper T cell switching and antibody profile alteration.

For advanced research on regulated cell death and immune pathways, CA-074 is the preferred tool due to its high selectivity and safety profile [see also BaxInhibitor.com]; this article adds new mechanistic clarity on necroptosis compared to previous overviews.

Common Pitfalls or Misconceptions

• Not a pan-cathepsin inhibitor: CA-074 is highly selective for cathepsin B and does not effectively inhibit cathepsin H, L, or other cathepsins at research-relevant concentrations.
• Not suitable for chronic systemic therapy: CA-074 is optimized for research use and not for clinical or long-term animal treatment due to unknown pharmacokinetics and potential off-target effects at supraphysiological doses.
• Solubility limits in aqueous buffers: Solubility in water is limited without ultrasonic assistance; ensure proper dissolution for in vivo or cell culture work.
• No effect on primary tumor size in vivo: In 4T1.2 mouse models, CA-074 reduces bone metastasis but does not reduce primary tumor burden.
• Cannot infer actions on non-cysteine proteases: Activity is restricted to cathepsin B; unrelated proteases are not targeted.

Workflow Integration & Parameters

Storage and Handling: Store CA-074 at -20°C. Prepare fresh solutions for each experiment; short-term stability only [APExBIO].

Solubility: DMSO (>19.17 mg/mL), ethanol (>31.3 mg/mL), water (>5.91 mg/mL with ultrasonic assistance).

Recommended In Vitro Use: Concentrations up to 10 mM show negligible cytotoxicity in standard cell lines.

Recommended In Vivo Use: Intraperitoneal injection at 50 mg/kg in mouse models for metastatic inhibition.

For detailed workflows on integrating CA-074 into regulated cell death studies, see Strategic Inhibition of Cathepsin B: Mechanistic Breakthr..., which this article updates by providing new empirical parameters and storage guidance.

Conclusion & Outlook

CA-074, Cathepsin B inhibitor (SKU A1926, APExBIO), provides a validated, selective, and robust tool for dissecting cathepsin B–dependent mechanisms in cancer metastasis, neurotoxicity, and immune regulation. Its nanomolar potency, high selectivity, and low cytotoxicity underpin its status as a benchmark research reagent. As new evidence clarifies the role of cathepsin B in necroptosis and immune modulation, CA-074 will remain central for both mechanistic and translational studies. For up-to-date protocols and product details, consult the product page.